Topic
Obesity & metabolic: latest medical news
GLP-1s, diabetes, obesity and cardiometabolic medicine.
GLP-1 compounder issues recall for copycat Zepbound
Source: BioPharma Dive
A compounding pharmacy has recalled a compounded tirzepatide product that copies Zepbound, adding to concerns about knockoff weight-loss drugs that stay popular despite FDA warnings and legal pressure from Lilly and Novo.
Why it mattersPatients on compounded GLP-1s may not be visible in brand pharmacovigilance data, so clinicians should ask what product patients are actually injecting when assessing adverse events.
Hospital Glucose Meter Removal: Nova Biomedical Removes StatStrip Glucose Hospital Meter Systems
Source: FDA MedWatch
FDA posted a removal notice for StatStrip Glucose Hospital Meter Systems, which need a software update because glucose results could be assigned to the wrong patient.
Why it mattersA point-of-care result filed under the wrong patient can drive wrong insulin dosing; hospitals using StatStrip should confirm the software update and their barcode-scanning workflow.
Daily email: coming soon
The day's approvals, safety signals and trials, in five minutes.
An email edition is on the way. Until then, bookmark this page or follow the RSS feed, a new digest is published every day.
Join the email waitlistOpens your email app. We only use your address to tell you when the email edition launches.